<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04600934</url>
  </required_header>
  <id_info>
    <org_study_id>00103170</org_study_id>
    <nct_id>NCT04600934</nct_id>
  </id_info>
  <brief_title>Shockwave Assisted Large Bore Access</brief_title>
  <official_title>Shockwave Assisted Large Bore Access (TAVR, TEVAR, EVAR, FEVAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shockwave Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Annually, 150-200 TAVR with unilateral large bore access and 200 combined TEVAR/EVAR/FEVAR&#xD;
      with bilateral large bore access are performed at our institution. Nearly 50 percent of&#xD;
      patients fall outside IFU for access vessel size. Adjuncts described include iliac conduit,&#xD;
      crack and pave, balloon expandable sheaths, direct aortic puncture, transcaval delivery,&#xD;
      alternative access point (i.e axillary, carotid). Each of these adjuncts comes with&#xD;
      additional complication potential and by nature of being used less frequently than the&#xD;
      standard femoral access makes the procedure more challenging.&#xD;
&#xD;
      The intervention the use of the Shockwave Medical, Inc. Peripheral Lithoplasty® System to&#xD;
      achieve large bore access in patients whose vessels fall outside of the IFU suggested&#xD;
      dimensions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful advancement of planned large bore access device</measure>
    <time_frame>Day 1</time_frame>
    <description>Technical success-defined as successful advancement of planned large bore access device without use of additional adjuncts (stenting, repeat shockwave treatment, high pressure balloon, alternative access pathway)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Standard POBA (plain old balloon angioplasty)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The first 50 patients will be pre-treated with standard POBA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shockwave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second 50 patients will be treated primarily with Shockwave</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shockwave</intervention_name>
    <description>Shockwave Medical, Inc. Peripheral Lithoplasty® System</description>
    <arm_group_label>Shockwave</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Plain old balloon angioplasty</intervention_name>
    <description>POBA</description>
    <arm_group_label>Standard POBA (plain old balloon angioplasty)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Indicated for planned procedure requiring large bore (&gt;12 French sheath) access&#xD;
&#xD;
          -  Mental capacity to provide informed consent&#xD;
&#xD;
          -  Iliac access vessel demonstrates &gt;50% circumferential calcium&#xD;
&#xD;
          -  Iliac access vessel demonstrates maximum inner lumen diameter less than IFU for device&#xD;
             required&#xD;
&#xD;
          -  Iliac access vessel demonstrates maximum outer wall diameter greater than or equal to&#xD;
             IFU for device required&#xD;
&#xD;
          -  Preoperative CT angiogram, &lt;/= 5mm slices&#xD;
&#xD;
          -  Preoperative ABI/TP&#xD;
&#xD;
          -  Unsuccessful delivery of large bore sheath without adjunctive intervention&#xD;
&#xD;
             o Definition of unsuccessful = operator assessment of the following&#xD;
&#xD;
          -  Visible distortion of iliac artery calcification under fluoroscopy without forward&#xD;
             progress of device&#xD;
&#xD;
          -  Adverse forward pressure application by operator&#xD;
&#xD;
          -  Failure of device to track with external pressure applied to abdomen&#xD;
&#xD;
          -  Patient intolerance of advancement (pain response) in awake patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindicated for antiplatelet therapy (aspirin or plavix)&#xD;
&#xD;
          -  Planned iliofemoral surgical reconstruction in next 30 days&#xD;
&#xD;
          -  Prior common or external iliac artery stent placement&#xD;
&#xD;
          -  Prior aorto-iliac, aorto-femoral, or iliofemoral bypass present&#xD;
&#xD;
          -  Iliac access vessel demonstrates maximum outer wall diameter less than IFU for device&#xD;
             required&#xD;
&#xD;
          -  Inability to obtain preoperative CTA (contrast allergy, CKD, etc)&#xD;
&#xD;
          -  Inability to traverse iliac segment with wire&#xD;
&#xD;
          -  Emergent procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathew Wooster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Overstreet, MS</last_name>
    <phone>843-792-8896</phone>
    <email>overstrm@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morgan Overstreet</last_name>
      <phone>843-792-8896</phone>
      <email>overstrm@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Schaffner</last_name>
      <phone>843-792-7558</phone>
      <email>schaffne@musc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 19, 2020</study_first_submitted>
  <study_first_submitted_qc>October 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2020</study_first_posted>
  <last_update_submitted>July 17, 2021</last_update_submitted>
  <last_update_submitted_qc>July 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Mathew Wooster</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Vascular Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

